Rheumatology & Autoimmune

4+ day, 17+ hour ago   (282+ words) Adicet Bio has reported positive Phase I safety and efficacy data for prulacabtagene leucel (prula-cel), its investigational allogeneic gamma delta CAR T therapy, in patients with systemic lupus erythematosus (SLE), with or without lupus nephritis. All patients discontinued immunosuppressant treatment,…...

10+ hour, 42+ min ago   (158+ words) October 12, 2026 07:00 ET | Source: Zenas BioPharma Follow Zenas BioPharma – Phase 3 INDIGO open-label extension findings demonstrated sustained clinical activity of obexelimab – – Additional analyses of secondary endpoints showed that significantly fewer patients experienced clinically meaningful cumulative glucocorticoid toxicity at week 52 – – These new findings…...

3+ week, 3+ day ago   (243+ words) “Our results show that these proteins are not merely markers of cellular stress. They actively contribute to the transformation of cells within the synovial membrane and to the maintenance of inflammation,” explains Zoé Gendebien, researcher at the Rheumatology Laboratory (University…...

20+ hour, 28+ min ago   (681+ words) A Chinese case series of eleven children with lupus identifies headache, transverse sinus involvement, elevated CRP and thrombocytopenia as the hallmark features of cerebral venous sinus thrombosis, with early combined treatment yielding favorable outcomes. Among the many complications that systemic…...

1+ day, 33+ min ago   (75+ words) New research in mice shows that curli amyloid fibers from Salmonella and E. coli biofilms can drive the production of anti-C1q and anti-dsDNA autoantibodies, linking infection and dysbiosis to lupus kidney disease. Subject of Research: The induction of anti-C1q and anti-dsDNA…...

1+ week, 5+ day ago   (758+ words) Every patient evaluated in a small early-stage lupus trial has stopped taking immunosuppressant drugs after a single infusion of an experimental donor-derived cell therapy, Adicet Bio reported on Sept. 28. More than half of the patients followed for a full year…...

2+ day, 13+ hour ago   (103+ words) Victoria Werth, MD, of the University of Pennsylvania, discusses phase 2 findings showing that daxdilimab, an anti-ILT7 antibody that depletes plasmacytoid dendritic cells, improved skin activity in patients with discoid lupus at 2 doses vs placebo. She notes that improvement emerged by…...

2+ day, 22+ hour ago   (166+ words) Instead, older age at diagnosis was linked to a lower likelihood of receiving advanced therapy (HR per standard deviation, 0.74; 95% CI, 0.55-1.00). Additional exploratory analyses demonstrated that patients aged 62 years and older were significantly less likely to initiate treatment with a bDMARD…...

3+ day, 1+ hour ago   (492+ words) Both doses of the anti-ILT7 antibody daxdilimab reduced CLASI-A scores vs placebo at week 24 in moderate-to-severe, treatment-refractory discoid lupus. Daxdilimab, an anti-ILT7 antibody depleting plasmacytoid dendritic cells (pDCs), reduced disease activity vs placebo in moderate to severe discoid lupus erythematosus…...

3+ day, 3+ hour ago   (262+ words) AMONG PATIENTS with ankylosing spondylitis (AS), a validated five-protein plasma signature has been linked to high structural damage, researchers have found, suggesting that plasma protein signatures could complement imaging by capturing biological processes beyond systemic inflammation. Pathological bone formation in…...